Evaluating RTU Vials on Isolators, RABS and High-Speed Lines

Ready-to-use (RTU) vials should be evaluated as a defined combination of vial SKU, packaging, transfer route, barrier system and filling equipment. A nest or tray that fits the loading station has not yet demonstrated aseptic suitability, stable throughput or acceptable closure performance.

For pharmaceutical manufacturers and CDMOs, the practical question is: Can this configuration enter the protected area, move through every required operation and meet agreed acceptance criteria under the intended operating conditions? This guide sets out an evaluation method, not a claim that a particular LINUO vial has been validated on every OEM platform.

Define the configuration before discussing compatibility

Record the vial code and drawing revision, packaging format, stopper and cap, machine OEM and model, software or recipe revision, format parts, planned batch size and target speed. Identify whether the product is a liquid or will be lyophilized. Include each transfer device between unpacking and final inspection.

Bei RTU vials with Nest & Tub, review the vial, nest and tub drawings together. Check cavity pitch, locating datums, support height, gripping surfaces and lift clearance. Decide which operations occur in the nest and where de-nesting is required.

Bei RTU vials with Tray Packaging, review tray dimensions, cavity arrangement, stacking and separation, vial support and the unloading method. Do not transfer Nest & Tub dimensions, position counts or trial results to Tray. Likewise, a successful 2R trial does not qualify a 6R or 10R configuration.

Map bag opening and the aseptic boundary

Create a transfer map showing each packaging layer, the surface exposed when it is removed, the opening location, the handling device and the destination of discarded material. Distinguish external packaging surfaces from surfaces that enter the critical zone. Record how exposed vials and stopper-contact surfaces remain protected during each hand-off.

Review peel direction, lid or bag clearance, loose packaging, potential particle generation and the path of operators’ hands or robotic tooling. Where a surface treatment or bio-decontamination step is part of the facility’s transfer strategy, its effectiveness and compatibility need assessment for the actual materials and configuration. A supplier’s sterile package does not itself validate the customer’s transfer process.

High speed is an operating condition, not an alternative to an isolator or RABS. Evaluate both the barrier strategy and the operating speed. Apply the facility’s contamination control strategy and approved procedures when determining which studies and challenges are required.

Define exactly what “non-contact handling” covers

Separating vials in individual nest positions can reduce vial-to-vial contact while they remain supported in that configuration. It does not establish that glass never touches grippers, guides, starwheels, inspection equipment or other vials after unloading.

Document contact by operation: in-pack transport, de-nesting or tray unloading, filling, stoppering, lyophilizer transfer, crimping and inspection. Identify the material and location of intended contact, and examine unintended contact at transitions. The acceptance record should state which operations were observed and under what conditions.

A useful result describes the tested scope: “No vial-to-vial contact was observed during the documented transfer sequence at the recorded settings.” Use such wording only when an actual observation record supports it; it is not a universal product guarantee.

Plan interventions before the trial

List routine actions such as packaging removal and replenishment, alongside foreseeable corrective actions such as a mispick, tipped vial, jam, damaged container or inspection reject fault. Assign a safe response, the responsible role, restart conditions and disposition of affected units under the site’s procedures.

Record whether an intervention brings tooling or a glove near exposed vials, changes airflow protection or requires a barrier opening. Distinguish a mechanical engineering trial from aseptic process simulation. An engineering run can identify handling problems, but it does not replace the manufacturer’s aseptic process qualification or justify an unqualified intervention during production.

Challenge positioning, breakage and inspection risks

Build the protocol around observable failure modes rather than a general “compatible” label. The following checks are starting points to adapt with the equipment OEM, engineering and QA teams.

Broken glass requires defined containment, clearance, inspection and restart procedures. A run with no observed breakage should report its sample count, duration and conditions. It cannot establish zero breakage risk for all future batches.

Inspection should be assessed for the defects and operating conditions relevant to the selected SKU. Agreement on reject criteria alone is insufficient: confirm that detection and the physical reject mechanism work together. Do not describe an inspection system as detecting every defect without appropriate evidence.

Evaluate usable throughput, not just the machine setpoint

Agree trial speeds and durations before testing. Include the planned operating range and relevant loading, replenishment, restart and changeover conditions. Distinguish the configured machine speed from the actual throughput achieved during the observation period.

Record units presented, accepted units, rejects by cause, stoppage time, intervention count and changeover duration. Define the denominator for every rate and whether planned stops are included. Keep the sample plan and acceptance criteria with the results so that different trials can be compared fairly.

Use measurable conclusions such as “The tested configuration met the agreed throughput and handling criteria within the recorded operating range.” If a criterion is missed, document the issue, format-part or setting changes, and any repeat trial. Do not substitute “zero downtime” for this evidence.

Keep qualification responsibilities and limits visible

The packaging supplier provides configuration-specific drawings and available product documentation. The equipment OEM contributes machine-interface and format-part requirements. The drug manufacturer or CDMO remains responsible for assessing the configuration within its manufacturing process and quality system, with responsibilities agreed among the parties.

Mechanical fit, sterile barrier integrity and container-closure integrity of the filled, closed vial are different questions. A successful empty-vial handling trial does not demonstrate formulation compatibility, filled-product closure integrity or aseptic process performance. Lyophilized products additionally require assessment of the actual vial/stopper combination and loading, drying and closing process.

Start with a traceable trial record

Use the RTU Filling-Line Trial Worksheet to record the configuration, OEM, format parts, speeds, interventions, results and review decision. Complete one record for each defined configuration. The worksheet supports planning and documentation; it is not a signed validation report.

Before arranging samples, identify the appropriate Nest & Tub product or Tray product, then contact LINUO with the drawing revision and equipment requirements. Request a suitable route for any confidential technical documents.

Regulatory context and further reading

• European Commission: EudraLex Volume 4, Annex 1, Manufacture of Sterile Medicinal Products: regulatory context for contamination control and aseptic processing. It does not certify an individual vial or filling-line combination.
• FDA: Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice: guidance for aseptic manufacturing controls. It is not evidence of FDA approval of a packaging supplier.

The evaluation checklist above is general engineering guidance. Acceptance limits, study requirements and operating procedures must be defined for the actual product, equipment and facility; no completed customer trial or OEM endorsement is asserted here.